On the basis of end-use application, the global radiopharmaceuticals market is divided into two different types, including diagnostic centers and hospitals. Due to the substantial availability of competent medical practitioners in hospital radiology departments, the hospital segment is expected to hold a considerable share of this market during the forecast period. However, the growing number of diagnostic centers, particularly in developed nations such as the U.S. is likely to propel the global radiopharmaceuticals market forward over the forecast period, from 2021 to 2031
Radiopharmaceuticals are a class of radioactive substances that can be employed for diagnostic or therapeutic purposes. Chemicals that emit beta particles (positrons or electrons) or gamma rays are often employed for diagnostic purposes, whereas compounds that release Auger electrons or alpha particles are typically utilized for therapeutic purposes. Radiopharmaceuticals are referred to as "tracers" when they are utilized for diagnostic reasons. The quantity of radiation in diagnostic radiopharmaceuticals is lower than in therapy radiopharmaceuticals.
Radiopharmaceuticals are basically unique therapeutic compositions that incorporate radioisotopes. These radiopharmaceuticals are utilized for both diagnosis and treatment. Radiopharmaceuticals are classified into four different categories, which are radiopharmaceutical preparation, radionuclide generator, radiopharmaceutical precursor, and radiopharmaceutical preparation kit.
The global radiopharmaceuticals market is driven by the rise in patient awareness, demand for precise diagnosis, increasing demand for disease-targeted cancer therapy, and the growing uses of molecular imaging. The utilization of monoclonal antibodies and radiolabeled peptides for the identification and treatment of malignant tumors (referred to as radiopharmaceutical-based customized therapy) is likely to fuel the growth of the global market for radiopharmaceuticals. The market research report examines the radiopharmaceutical sector in further depth, offering a comprehensive view of market dynamics, patient preferences, illness trends, and supply and demand.
In the last few decades, nuclear medicine has acquired a lot of popularity. The availability of 99m Tc, an isotope used in 80% of diagnostic procedures, is primarily responsible for nuclear medicine's expanding popularity. At present, about 25 million diagnostic procedures involving 99m Tc radiopharmaceuticals are performed yearly, with trends indicating that this number is likely to rise. The availability of short-lived 99m Tc is one of the key factors likely to drive the adoption of Technetium 99. At present, research and development operations are in full swing to boost 99 Mo's total production capacity, which is expected to have a beneficial influence on 99m Tc output.
In the current situation, 99m Tc is widely employed in a variety of diagnostic procedures, such as neuroendocrine tumor imaging and thyroid uptake pertechnetate. In the last few years, there has been a tremendous increase in research activity aimed at developing new and better 99m Tc radiopharmaceuticals. 99m Tc is predicted to dominate the global radiopharmaceutical market throughout the forecast timeframe, from 2021 to 20321, as applications of 99m Tc for dynamic and morphological imaging of the liver, kidneys, and bone are expected to rise. In addition, due to their widespread availability and low prices, various radiopharmaceuticals are expected to gain popularity.
North America, Latin America, Asia Pacific, Europe, the Middle East, and Africa are the four primary regions that make up the global radiopharmaceuticals business. In 2020, the global radiopharmaceuticals market was headed by North America, trailed by Europe. Due to a rise in PET-CT scanner equipment installations and increased demand for disease risk assessment services for cancer treatment, North America held a large part of the global market for radiopharmaceuticals in 2020. From 2021 to 2031, the radiopharmaceuticals market in Asia Pacific is expected to rise at a rapid growth rate. The global market in the region is expected to be driven by product launches, acquisitions, distribution agreements, partnerships, and regional growth by local companies, particularly in India and China.
The global market is projected to reach a value of US$ 8.5 Bn by 2031 end
The market for radiopharmaceuticals is anticipated to grow at a CAGR of 7.3% during the forecast period
The end-user segments in the global market are hospitals, diagnostic labs, and others
The tc-99 segment is anticipated to account for a major share of the global market for radiopharmaceuticals by 2031
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiopharmaceuticals Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Radiopharmaceuticals Market Analysis and Forecast, 2017-2031
5. Market Outlook
5.1. COVID-19 Pandemics Impact on Industry
5.2. Key Industry Events
5.3. No. of Nuclear Medicine Centers in Major Countries
5.4. List of FDA Approved Radioisotopes
6. Global Radiopharmaceuticals Market Analysis and Forecast, by Compound
6.1. Introduction & Definition
6.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017-2031
6.2.1. Fluorine-18 Derivatives
6.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)
6.2.1.2. Fluorine-18 Sodium Fluoride
6.2.1.3. Fluorine-18 Flucicovine
6.2.1.4. Fluorine-18 Florbetapir
6.2.1.5. Fluorine-18 Florbetaben
6.2.1.6. Others
6.2.2. Technetium-99
6.2.3. Lutetium (Lu) 177
6.2.4. Gallium-68
6.2.4.1. Dotatate
6.2.4.2. Dotatoc
6.2.5. Zirconium 89
6.2.6. 11C-choline
6.2.7. 14C-urea
6.2.8. Others
6.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Compound
7. Global Radiopharmaceuticals Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017-2031
7.2.1. Diagnosis
7.2.2. Neurology
7.2.2.1. Neurodegenerative Disease (AD, PD, and Others)
7.2.2.2. Epilepsy
7.2.3. Cardiology
7.2.4. Others
7.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Indication
8. Global Radiopharmaceuticals Market Analysis and Forecast, by System
8.1. Introduction & Definition
8.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017-2031
8.2.1. PET
8.2.1.1. Standalone PET systems
8.2.1.2. Hybrid PET/CT
8.2.1.3. Hybrid PET/MRI
8.2.2. SPECT
8.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by System
9. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017-2031
9.2.1. Hospitals
9.2.2. Diagnostic Labs
9.2.3. Others
9.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by End-user
10. Global Radiopharmaceuticals Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Rest of the World
10.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Region
11. North America Radiopharmaceuticals Market Analysis and Forecast
11.1. Introduction
11.2. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017-2031
11.2.1. Fluorine-18 Derivatives
11.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)
11.2.1.2. Fluorine-18 Sodium Fluoride
11.2.1.3. Fluorine-18 Flucicovine
11.2.1.4. Fluorine-18 Florbetapir
11.2.1.5. Fluorine-18 Florbetaben
11.2.1.6. Others
11.2.2. Technetium-99
11.2.3. Lutetium (Lu) 177
11.2.4. Gallium-68
11.2.4.1. Dotatate
11.2.4.2. Dotatoc
11.2.5. Zirconium 89
11.2.6. 11C-choline
11.2.7. 14C-urea
11.2.8. Others
11.3. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017-2031
11.3.1. Diagnosis
11.3.2. Neurology
11.3.2.1. Neurodegenerative Disease (AD, PD, and Others)
11.3.2.2. Epilepsy
11.3.3. Cardiology
11.3.4. Others
11.4. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017-2031
11.4.1. PET
11.4.1.1. Standalone PET systems
11.4.1.2. Hybrid PET/CT
11.4.1.3. Hybrid PET/MRI
11.4.2. SPECT
11.5. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Diagnostic Labs
11.5.3. Others
11.6. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. North America PET-CT Scanner Devices Market Attractiveness Analysis
11.7.1. By Compound
11.7.2. By Indication
11.7.3. By System
11.7.4. End-user
11.7.5. By Country
12. Europe Radiopharmaceuticals Market Analysis and Forecast
12.1. Introduction
12.2. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017-2031
12.2.1. Fluorine-18 Derivatives
12.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)
12.2.1.2. Fluorine-18 Sodium Fluoride
12.2.1.3. Fluorine-18 Flucicovine
12.2.1.4. Fluorine-18 Florbetapir
12.2.1.5. Fluorine-18 Florbetaben
12.2.1.6. Others
12.2.2. Technetium-99
12.2.3. Lutetium (Lu) 177
12.2.4. Gallium-68
12.2.4.1. Dotatate
12.2.4.2. Dotatoc
12.2.5. Zirconium 89
12.2.6. 11C-choline
12.2.7. 14C-urea
12.2.8. Others
12.3. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017-2031
12.3.1. Diagnosis
12.3.2. Neurology
12.3.2.1. Neurodegenerative Disease (AD, PD, and Others)
12.3.2.2. Epilepsy
12.3.3. Cardiology
12.3.4. Others
12.4. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017-2031
12.4.1. PET
12.4.1.1. Standalone PET systems
12.4.1.2. Hybrid PET/CT
12.4.1.3. Hybrid PET/MRI
12.4.2. SPECT
12.5. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Diagnostic Labs
12.5.3. Others
12.6. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Radiopharmaceuticals Market Attractiveness Analysis
12.7.1. By Compound
12.7.2. By Indication
12.7.3. By Systems
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017-2031
13.2.1. Fluorine-18 Derivatives
13.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)
13.2.1.2. Fluorine-18 Sodium Fluoride
13.2.1.3. Fluorine-18 Flucicovine
13.2.1.4. Fluorine-18 Florbetapir
13.2.1.5. Fluorine-18 Florbetaben
13.2.1.6. Others
13.2.2. Technetium-99
13.2.3. Lutetium (Lu) 177
13.2.4. Gallium-68
13.2.4.1. Dotatate
13.2.4.2. Dotatoc
13.2.5. Zirconium 89
13.2.6. 11C-choline
13.2.7. 14C-urea
13.2.8. Others
13.3. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017-2031
13.3.1. Diagnosis
13.3.2. Neurology
13.3.2.1. Neurodegenerative Disease (AD, PD, and Others)
13.3.2.2. Epilepsy
13.3.3. Cardiology
13.3.4. Others
13.4. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017-2031
13.4.1. PET
13.4.1.1. Standalone PET systems
13.4.1.2. Hybrid PET/CT
13.4.1.3. Hybrid PET/MRI
13.4.2. SPECT
13.5. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Diagnostic Labs
13.5.3. Others
13.6. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis
13.7.1. By Compound
13.7.2. By Indication
13.7.3. By Systems
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Rest of the World Radiopharmaceuticals Market Analysis and Forecast
14.1. Introduction
14.2. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017-2031
14.2.1. Fluorine-18 Derivatives
14.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)
14.2.1.2. Fluorine-18 Sodium Fluoride
14.2.1.3. Fluorine-18 Flucicovine
14.2.1.4. Fluorine-18 Florbetapir
14.2.1.5. Fluorine-18 Florbetaben
14.2.1.6. Others
14.2.2. Technetium-99
14.2.3. Lutetium (Lu) 177
14.2.4. Gallium-68
14.2.4.1. Dotatate
14.2.4.2. Dotatoc
14.2.5. Zirconium 89
14.2.6. 11C-choline
14.2.7. 14C-urea
14.2.8. Others
14.3. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017-2031
14.3.1. Diagnosis
14.3.2. Neurology
14.3.2.1. Neurodegenerative Disease (AD, PD, and Others)
14.3.2.2. Epilepsy
14.3.3. Cardiology
14.3.4. Others
14.4. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017-2031
14.4.1. PET
14.4.1.1. Standalone PET systems
14.4.1.2. Hybrid PET/CT
14.4.1.3. Hybrid PET/MRI
14.4.2. SPECT
14.5. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Diagnostic Labs
14.5.3. Others
14.6. Rest of the World Radiopharmaceuticals Market Attractiveness Analysis
14.6.1. By Compound
14.6.2. By Indication
14.6.3. By System
14.6.4. By End-user
15. Competition Landscape
15.1. Company Profiles
15.1.1. Advanced Accelerator Applications (a Novartis AG Company)
15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.1.2. Growth Strategies
15.1.1.3. SWOT Analysis
15.1.2. Siemens Healthineers AG
15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.2.2. Growth Strategies
15.1.2.3. SWOT Analysis
15.1.3. Jubilant Pharma Limited
15.1.3.1. Company Overview (HQ, Business Segments)
15.1.3.2. Growth Strategies
15.1.3.3. SWOT Analysis
15.1.4. GE Healthcare
15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.4.2. Growth Strategies
15.1.4.3. SWOT Analysis
15.1.5. Bayer AG
15.1.5.1. Company Overview (HQ, Business Segments)
15.1.5.2. Growth Strategies
15.1.5.3. SWOT Analysis
15.1.6. ITM Isotopen Technologien München AG
15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.6.2. Growth Strategies
15.1.6.3. SWOT Analysis
15.1.7. Telix Pharmaceuticals
15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.7.2. Growth Strategies
15.1.7.3. SWOT Analysis
15.1.8. Lantheus Holdings, Inc.
15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.8.2. Growth Strategies
15.1.8.3. SWOT Analysis
15.1.9. Eli Lilly and Company
15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.9.2. Growth Strategies
15.1.9.3. SWOT Analysis
15.1.10. Nihon Medi-Physics
15.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.10.2. Growth Strategies
15.1.10.3. SWOT Analysis
15.1.11. Avanos Medical, Inc.
15.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.11.2. Growth Strategies
15.1.11.3. SWOT Analysis
List of Tables
Table 01: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Compound, 2017-2031
Table 02: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017-2031
Table 03: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Gallium-68, 2017-2031
Table 04: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017-2031
Table 05: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017-2031
Table 06: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017-2031
Table 07: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017-2031
Table 08: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017-2031
Table 09: Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 10: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 11: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017-2031
Table 12: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017-2031
Table 13: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017-2031
Table 14: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017-2031
Table 15: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System (PET), 2017-2031
Table 16: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017-2031
Table 17: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017-2031
Table 18: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017-2031
Table 19: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 20: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017-2031
Table 21: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017-2031
Table 22: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017-2031
Table 23: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017-2031
Table 24: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017-2031
Table 25: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017-2031
Table 26: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017-2031
Table 27: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017-2031
Table 28: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 29: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017-2031
Table 30: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017-2031
Table 31: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017-2031
Table 32: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017-2031
Table 33: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017-2031
Table 34: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017-2031
Table 35: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017-2031
Table 36: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017-2031
Table 37: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017-2031
Table 38: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017-2031
Table 39: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017-2031
Table 40: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017-2031
Table 41: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017-2031
Table 42: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017-2031
Table 43: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017-2031
Table 44: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Radiopharmaceuticals Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 02: Global PET-CT Scanner Devices Market Value Share, by Region, 2020
Figure 03: Global Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031
Figure 04: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Technetium-99, 2017-2031
Figure 05: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Gallium-68, 2017-2031
Figure 06: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Fluorine-18 Derivatives, 2017-2031
Figure 07: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Lu-177, 2017-2031
Figure 08: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Zirconium89, 2017-2031
Figure 09: Global Radiopharmaceuticals Market Revenue (US$ Mn), by 11C-choline, 2017-2031
Figure 10: Global Radiopharmaceuticals Market Revenue (US$ Mn), by 14C-urea, 2017-2031
Figure 11: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017-2031
Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021-2031
Figure 13: Global Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031
Figure 14: Global Radiopharmaceuticals Market Revenue (US$ Mn), by PET, 2017-2031
Figure 15: Global Radiopharmaceuticals Market Revenue (US$ Mn), by SPECT, 2017-2031
Figure 16: Global Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021-2031
Figure 17: Global Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031
Figure 18: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Oncology, 2017-2031
Figure 19: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Cardiology, 2017-2031
Figure 20: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Neurology, 2017-2031
Figure 21: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017-2031
Figure 22: Global Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021-2031
Figure 23: Global Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031
Figure 24: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Diagnostic Lab, 2017-2031
Figure 25: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Hospitals, 2017-2031
Figure 26: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017-2031
Figure 27: Global Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021 -2031
Figure 28: Global Radiopharmaceuticals Market Value Share Analysis, by Region, 2020 and 2031
Figure 29: Global Radiopharmaceuticals Market Attractiveness Analysis, by Region, 2021-2031
Figure 30: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017-2031
Figure 31: North America Radiopharmaceuticals Market Value Share Analysis, by Country, 2020 and 2031
Figure 32: North America Radiopharmaceuticals Market Attractiveness Analysis, by Country, 2021-2031
Figure 33: North America Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031
Figure 34: North America Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021-2031
Figure 35: North America Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031
Figure 36: North America Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021-2031
Figure 37: North America Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031
Figure 38: North America Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021-2031
Figure 39: North America Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031
Figure 40: North America Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021-2031
Figure 41: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017-2031
Figure 42: Europe Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 43: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 44: Europe Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031
Figure 45: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021-2031
Figure 46: Europe Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031
Figure 47: Europe Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021-2031
Figure 48: Europe Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031
Figure 49: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021-2031
Figure 50: Europe Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031
Figure 51: Europe Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021-2031
Figure 52: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017-2031
Figure 53: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 54: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 55: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031
Figure 56: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021-2031
Figure 57: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031
Figure 58: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021-2031
Figure 59: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031
Figure 60: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021-2031
Figure 61: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031
Figure 62: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021-2031
Figure 63: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017-2031
Figure 64: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031
Figure 65: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021-2031
Figure 66: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031
Figure 67: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021-2031
Figure 68: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031
Figure 69: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021-2031
Figure 70: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031
Figure 71: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Radiopharmaceuticals Market
